Mabwell Clears Brazilian ANVISA GMP Inspection for Denosumab Biosimilars, Paving Way for Latin American Market Access
核心洞察
Mabwell (搜索)'s subsidiary T-mab (搜索) successfully passed ANVISA's GMP on-site inspection for its denosumab biosimilars 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar).
This marks Mabwell (搜索)'s second GMP certification from a PIC/S member authority, following Jordan, and validates the company's quality management system against ICH and WHO standards.
Brazil represents Latin America's largest pharmaceutical market, and the approval facilitates broader access to PIC/S member markets.
Shanghai-based Mabwell (搜索), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary T-mab (搜索) has successfully passed the Brazilian Health Regulatory Agency's (ANVISA) GMP on-site inspection for its two denosumab biosimilars — 9MW0311, a biosimilar referencing Prolia®, and 9MW0321, a biosimilar referencing Xgeva®. The achievement, disclosed on August 10, 2026, marks Mabwell's second GMP certification from a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member authority, following a prior certification in Jordan.
Strategic Significance of the Brazilian Market
As a BRICS nation and Latin America's largest economy, Brazil boasts the region's biggest pharmaceutical market. ANVISA, as a PIC/S member, is recognized for its rigorous GMP standards that are fully aligned with International Council for Harmonisation (ICH) and World Health Organization (WHO) guidelines. Successfully passing this on-site inspection represents a strong vote of confidence in Mabwell (搜索)'s quality management system and manufacturing capabilities.
The certification is expected to serve as a gateway for Mabwell (搜索)'s denosumab biosimilars to reach a broader patient population across PIC/S member markets, which share harmonized regulatory standards and mutual recognition frameworks.
Regulatory Progress and Global Expansion
Mabwell (搜索) has been actively pursuing a global regulatory strategy for its denosumab portfolio. The company had already submitted market authorization applications for its denosumab products in eight countries, including Brazil, prior to this GMP milestone. Additionally, Mabwell has obtained marketing approval in Pakistan, demonstrating tangible progress in its international commercialization efforts.
Denosumab, a monoclonal antibody targeting RANKL (搜索), is indicated for osteoporosis (搜索) (Prolia®) and for the prevention of skeletal-related events in patients with bone metastases from solid tumors (Xgeva®). Mabwell (搜索)'s biosimilar versions aim to expand patient access to these therapies in emerging markets where cost and availability remain significant barriers.
The successful ANVISA inspection underscores the growing capability of Chinese biopharmaceutical companies to meet stringent international manufacturing standards and positions Mabwell (搜索) for continued expansion across Latin America and other PIC/S-aligned regulatory jurisdictions.